AnaptysBio Appoints Paul Lizzul as Its Chief Medical Officer

Paul Lizzul has joined AnaptysBio (NASDAQ: [[ticker:ANAB]]) as the company’s chief medical officer. He succeeds Marco Londei, who held the roles of CMO and chief development officer at AnaptysBio until earlier this year, when he joined Dutch biotech Gadeta as CEO.

Lizzul most recently served a short stint at Amgen (NASDAQ: [[ticker:AMGN]]) as global development lead for inflammation. Previously he was CMO at Sienna Biopharmaceuticals, which shuttered in 2019, and senior medical director at cosmetic drug company Kythera Biopharmaceuticals, which Allergan acquired for $2.1 billion in 2015. San Diego-based AnaptysBio is developing antibodies to treat inflammatory disorders; the company has advanced seven programs into the clinic.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine. View all posts by Sarah de Crescenzo